126 related articles for article (PubMed ID: 38448374)
1. Diagnostic value of
Guo S; Zhou C; Zhang Y; Wang D; Niu T; Zhou F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 48(12):1812-1819. PubMed ID: 38448374
[TBL] [Abstract][Full Text] [Related]
2.
Yang J; Li J; Xiao L; Zhou M; Fang Z; Cai Y; Tang Y; Hu S
Cancer Imaging; 2023 Sep; 23(1):81. PubMed ID: 37667341
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer.
Zou BZ; Wen H; Luo HJ; Luo WC; Xie QT; Zhou MT
Ir J Med Sci; 2023 Dec; 192(6):2681-2687. PubMed ID: 37414978
[TBL] [Abstract][Full Text] [Related]
5.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
6. Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI,
Akkaya H; Dilek O; Özdemir S; Taş ZA; Öztürk İS; Gülek B
Diagn Interv Radiol; 2023 Sep; 29(5):647-655. PubMed ID: 37395389
[TBL] [Abstract][Full Text] [Related]
7.
Liu C; Liu T; Zhang Z; Zhang N; Du P; Yang Y; Liu Y; Yu W; Li N; Gorin MA; Rowe SP; Zhu H; Yan K; Yang Z
J Nucl Med; 2020 Sep; 61(9):1314-1319. PubMed ID: 32034111
[TBL] [Abstract][Full Text] [Related]
8. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
9. Significant Diagnostic Value of Free-Serum PSA (FPSA)/Prostate-Specific Antigen Density (PSAD) and (F/T)/PSAD for Prostate Cancer of the Chinese Population in a Single Institution.
Nan LB; Yin XT; Gao JP
Med Sci Monit; 2019 Nov; 25():8345-8351. PubMed ID: 31691648
[TBL] [Abstract][Full Text] [Related]
10. A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [
Lv J; Yu H; Yin H; Shi Y; Shi H
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):919-927. PubMed ID: 37940684
[TBL] [Abstract][Full Text] [Related]
11. The use of
Yang J; Tang Y; Zhou C; Zhou M; Li J; Hu S
Prostate; 2023 Apr; 83(5):430-439. PubMed ID: 36544382
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of
Rahbar K; Afshar-Oromieh A; Seifert R; Wagner S; Schäfers M; Bögemann M; Weckesser M
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2055-2061. PubMed ID: 30027419
[TBL] [Abstract][Full Text] [Related]
13. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
14. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the value of
Luo L; Zheng A; Chang R; Li Y; Gao J; Wang Z; Duan X
Cancer Imaging; 2023 Nov; 23(1):108. PubMed ID: 37924154
[TBL] [Abstract][Full Text] [Related]
16. Machine learning-based prediction of invisible intraprostatic prostate cancer lesions on
Yi Z; Hu S; Lin X; Zou Q; Zou M; Zhang Z; Xu L; Jiang N; Zhang Y
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1523-1534. PubMed ID: 34845536
[TBL] [Abstract][Full Text] [Related]
17. Potential diagnostic value of multiple indicators combined with total prostate-specific antigen in prostate cancer.
Zhang Q; Li H; Song Z; Kong S; Zhao S; Fan S; Qin F; Ma J
J Int Med Res; 2023 Oct; 51(10):3000605231204429. PubMed ID: 37848343
[TBL] [Abstract][Full Text] [Related]
18. [Application of dynamic contrast enhanced status in multiparametric magnetic resonance imaging for prostatic cancer with PI-RADS 4 lesion].
Yuan CW; Li R; Li ZH; Liu Y; Shan GZ; Li XS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):838-842. PubMed ID: 37807737
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of prostate PI-RADS V2.1 score combined with serum PSA-related indicators in the detection of gray zone prostate cancer.
Lin S; Yu X; Chen H; Chen Z; Yang Y
Int Urol Nephrol; 2023 Nov; 55(11):2685-2693. PubMed ID: 37523077
[TBL] [Abstract][Full Text] [Related]
20. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
